Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Shareholder Meeting (March 2013)
22 slides from Agilent Technologies's shareholder meeting presentation, Mar 20, 2013
Slide 1: Agilent Technologies Annual Shareholder Meeting
Agilent Technologies Annual Shareholder Meeting March 20, 2013
Slide 2: James G. Cullen, Non-Executive Chairman of the Board
Agilent Technologies James G. Cullen Non-Executive Chairman of the Board
Slide 3: William P. (Bill) Sullivan, Chief Executive Officer
Agilent Technologies William P. (Bill) Sullivan Chief Executive Officer
Slide 4: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on our goals, priorities, revenues, demand, growth opportunities, customer service and innovation plans, new product introductions, financial condition, earnings, the con
Slide 5: The World’s Premier Measurement Company
The World’s Premier Measurement Company FY12 Revenue $6.9B, Growth +4%, Operating Margin* 20%, Operating Cash Flow $1.2B Diagnostics & Chemical Electronic Life Sciences Genomics Analysis Measurement FY12 Revenue $0.4B FY12 Revenue $1.6B FY12 Revenue $1.6B FY12 Revenue $3.3B Operating Margin 16% Oper
Slide 6: Diagnostics and Genomics Group Overview
Diagnostics and Genomics Group Overview Market Size*: $7B Long Term Market Growth*: 8-10% 2012 DGG Revenue $402M 2012 Operating Margin 16% Markets & Market Position Revenue Mix Anatomic Pathology #2 by Geography Molecular Americas Europe Diagnostics Emerging DGG also sells into the pharmaceutical As
Slide 7: Diagnostics and Genomics Group
Diagnostics and Genomics Group Pathology Lab Workflow Doctor / Oncologist Processing • Dako: “Connecting to fight Grossing Embedding Surgery cancer” Specimen Receiving and Data Entry Sectioning • Anatomic pathology: workflow solutions for the pathology lab • Companion diagnostics: collaboration agre
Slide 8: Life Sciences Group Overview
Life Sciences Group Overview Market Size*: $21B Long Term Market Growth*: 4-5% 2012 LSG Revenue $1.6B 2012 Operating Margin 15% 19% Excl. RPD** Markets & Market Position Revenue Mix Pharma & Biotech #3 by Geography Academia & Europe Americas Government #4#4 Research #1 in Liquid Chromatography (LC)
Slide 9: Life Sciences Group
Life Sciences Group • LCMS: one of Agilent’s biggest 14% CAGR success stories • First entered high-end market in 2007 • Leveraged entire company: • EMG: RF modulation, A-to-D converters • CAG: GCMS • Currently the broadest family in the industry – close to No. 1 in QQQ marketshare • The industry wor
Slide 10: Chemical Analysis Group Overview
Chemical Analysis Group Overview Market Size*: $13B Long Term Market Growth*: 4-5% 2012 CAG Revenue $1.6B 2012 Operating Margin 22% Markets and Market Position Revenue Mix by Geography Americas Europe Food Environmental Chemical #1 and Forensics and Energy #1 and #2 #1 Asia Pacific * Market size and
Slide 11: Chemical Analysis Group
Chemical Analysis Group • Making the world a safer and 4100 MP-AES healthier place Runs on air “2012 R&D 100 • Market growth driven by global Award Winner” trends: • Safety of global food supply • New environmental 7200 GC Q-TOF World’s first contaminants (air, water, soil) GC Q-TOF • Abuse of presc
Slide 12: Electronic Measurement Group Overview
Electronic Measurement Group Overview Market Size*: $13B Long Term Market Growth*: 3-4% 2012 EMG Revenue $3.3B 2012 Operating Margin 23% Markets & Market Position Revenue Mix Communications #1 by Geography Europe Industrial, Americas Computers, #1 Semiconductors Aerospace/Defense #1 Asia Pacific * M
Slide 13: Electronic Measurement Group
Electronic Measurement Group • Enabling and testing the next generation of electronics and communications Oscilloscopes Network Analyzers • Technology and market leadership • Industry-leading sales and Signal Analyzers Signal Sources support, with complementary direct and indirect sales • Market opp
Slide 14: Agilent Order Fulfillment Excellence
Agilent Order Fulfillment Excellence Operational Excellence • Gross margin improvement • Procurement leveraging • Value engineering • Supply chain streamlining Technology Excellence • Technology building blocks • Quick ramp-to-volume for new products Key manufacturing hubs Best Customer Experience •
Slide 15: FY 2013 Priorities
FY 2013 Priorities • Increase organic growth rate Invest in market expansion and R&D • Improve gross margins Multi-year effort to reduce manufacturing and logistics costs by $180M – one-third complete • Ensure Dako success Launch autostainer, leverage our genomics and pathology businesses Annual Sha
Slide 16: Agilent Technologies Annual Shareholder Meeting
Agilent Technologies Annual Shareholder Meeting March 20, 2013
Slide 17: Reconciliations
Agilent Technologies Reconciliations
Slide 18: Electronic Measurement Segment
AGILENT TECHNOLOGIES, INC. ELECTRONIC MEASUREMENT SEGMENT (Unaudited) PRELIMINARY (In millions, except margins and ROIC data) FY 2012 Q1 Q2 Q3 Q4 Total Orders $ 757 $ 957 $ 811 $ 755 $ 3,280 Net revenue $ 778 $ 876 $ 845 $ 816 $ 3,315 Gross margin % 57.8% 57.0% 55.9% 57.1% 56.9% Income from operatio
Slide 19: Chemical Analysis Segment
AGILENT TECHNOLOGIES, INC. CHEMICAL ANALYSIS SEGMENT (Unaudited) PRELIMINARY (In millions, except margins and ROIC data) FY 2012 Q1 Q2 Q3 Q4 Total Orders $ 403 $ 408 $ 372 $ 421 $ 1,604 Net revenue $ 396 $ 388 $ 381 $ 394 $ 1,559 Gross margin % 51.7% 50.8% 50.1% 52.9% 51.4% Income from operations $
Slide 20: Life Sciences Segment
AGILENT TECHNOLOGIES, INC. LIFE SCIENCES SEGMENT (Unaudited) PRELIMINARY (In millions, except margins and ROIC data) FY 2012 Q1 Q2 Q3 Q4 Total Orders $ 394 $ 410 $ 373 $ 417 $ 1,594 Net revenue $ 395 $ 395 $ 391 $ 401 $ 1,582 Gross margin % 50.9% 48.9% 50.5% 52.8% 50.8% Income from operations $ 58 $
Slide 21: Diagnostics and Genomics Segment
AGILENT TECHNOLOGIES, INC. DIAGNOSTICS AND GENOMICS SEGMENT (Unaudited) PRELIMINARY (In millions, except margins and ROIC data) FY 2012 Q1 Q2 Q3 Q4 Total Orders $ 69 $ 66 $ 106 $ 158 $ 399 Net revenue $ 66 $ 74 $ 106 $ 156 $ 402 Gross margin % 62.6% 65.3% 60.8% 63.4% 62.9% Income from operations $ 8
Slide 22: Reconciliation from GAAP to Non-GAAP
AGILENT TECHNOLOGIES, INC RECONCILIATION FROM GAAP TO NON-GAAP YEAR ENDED October 31, 2012 (Unaudited) PRELIMINARY NON-GAAP ADJUSTMENTS Acquisition & Agilent Asset Intangible Transformational Integration Foundation Adjustment (In millions, except per share amounts) GAAP Impairments Amortization Init
Agilent Technologies — Shareholder Meeting (March 2013) on 6ix